Therapeutics for mpox

Publication Summary

There are two anti-viral treatments used for smallpox that have been repurposed for mpox, tecovirimat and brincidofovir, of which only the former has been approved for clinical use in Canada. Tecovirimat works by blocking the interaction of viral p37 protein orthologs and preventing the envelopment and release of orthopoxviruses from infected cells. According to one patient study, treatment of mpox using tecovirimat was associated with shorter hospitalization and reduced viral shedding.